Omnicell, Inc. (NASDAQ:OMCL) Receives $82.75 Consensus Target Price from Analysts
Omnicell, Inc. (NASDAQ:OMCL) has been assigned a consensus recommendation of “Buy” from the eleven ratings firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $82.75.
OMCL has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research report on Monday, July 29th. Sidoti set a $82.00 target price on shares of Omnicell and gave the stock a “hold” rating in a research report on Friday, October 25th. ValuEngine lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. BidaskClub upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 12th. Finally, Craig Hallum upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Friday, July 26th.
In other Omnicell news, CEO Randall A. Lipps sold 25,926 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $78.03, for a total transaction of $2,023,005.78. Following the completion of the transaction, the chief executive officer now owns 128,487 shares in the company, valued at $10,025,840.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Dan S. Johnston sold 6,250 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $71.71, for a total transaction of $448,187.50. Following the transaction, the executive vice president now owns 27,826 shares of the company’s stock, valued at approximately $1,995,402.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,182 shares of company stock valued at $3,155,979. 2.77% of the stock is owned by company insiders.
Shares of OMCL traded up $1.80 during mid-day trading on Monday, reaching $73.89. The stock had a trading volume of 161,500 shares, compared to its average volume of 331,602. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of 48.29, a PEG ratio of 2.80 and a beta of 1.08. Omnicell has a 12 month low of $56.96 and a 12 month high of $92.59. The business has a fifty day moving average of $73.22 and a 200 day moving average of $76.32. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.63 and a current ratio of 2.09.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.05. The business had revenue of $228.80 million during the quarter, compared to analyst estimates of $231.86 million. Omnicell had a net margin of 6.28% and a return on equity of 11.90%. The company’s revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. On average, research analysts forecast that Omnicell will post 2.09 EPS for the current fiscal year.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: How to invest using market indexes
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.